2.515USD-5.09%Mkt Cap: 368.96M USDP/E: —Last update: 2026-05-26
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap368.96M USD
Enterprise Value340.28M USD
Revenue (TTM)28.94M USD
Gross Profit18.36M USD
Net Income (TTM)-64.78M USD
Revenue/Share0.2430 USD
Last Price2.515 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees89
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.91
PEG—
EV/EBITDA-10.18
EV/Revenue11.76
P/S12.77
P/B1.41
EPS (TTM)-0.46
EPS (Forward)-0.32
52W Range
1.22086% of range2.730
52W High2.730 USD
52W Low1.220 USD
Profitability
Gross Margin98.38%
Oper. Margin-54.27%
EBITDA Margin-115.54%
Profit Margin-347.04%
ROE-24.26%
ROA-21.53%
Growth
Revenue Growth247.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.45M USD
CapEx (TTM)565.00K USD
FCF Margin-8.89%
FCF Yield-0.70%
Net Debt-29.40M USD
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity0.08
Current Ratio4.80
Quick Ratio4.55
Book Value/Sh1.814 USD
Cash/Share0.3380 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)7.333 USD
Target Range3.000 USD – 11.00 USD
# Analysts6
Ownership
Shares Out.144.97M
Float97.53M
Insiders15.24%
Institutions50.96%
Short Interest
Short Ratio9.5d
Short % Float3.98%
Short % Out.3.63%
Shares Short5.26M
Short (prev mo.)5.95M
Technical
SMA 501.676 (+50.0%)
SMA 2001.741 (+44.4%)
Beta0.62
S&P 52W Chg28.31%
Avg Vol (30d)922.38K
Avg Vol (10d)1.50M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—